GLP-1 medications reduce appetite, and when total intake falls quickly, lean mass can fall with the fat. A 2026 systematic review and meta-analysis of seven randomized controlled trials, covering 821 patients on obesity-dose GLP-1 receptor agonists, reported a mean absolute lean mass change of −1.74 kg. That is the number to plan around, and the plan is protein, resistance training, and monitoring of function — started at the same time as the medication, not after weakness shows up.
Key takeaways
- In July 2026, Gallup reported that 11% of U.S. adults currently take a GLP-1 medication for weight loss, up from prior years.
- In a 2026 meta-analysis of 821 patients on obesity-dose GLP-1 receptor agonists, absolute lean mass fell by a mean of 1.74 kg, while lean mass as a proportion of total body weight rose by 1.81%.
- Those two findings are not in conflict. Body composition can improve on a percentage basis while you still lose real muscle tissue.
- Protein intake and structured resistance exercise are the levers with the strongest support, and they work together rather than as alternatives.
- Watch function, not only the scale: stair tolerance, recovery time, and the ability to rise from a chair.
- Joint pain that blocks training is a muscle problem as much as a joint problem, which is where a conservative-first orthopedic plan matters.
Why lean mass falls during GLP-1 treatment
Intake drops faster than habits adapt
GLP-1 medications work largely by reducing appetite and slowing gastric emptying, so total intake can drop sharply within weeks. When intake falls that fast, protein often falls with it, and the body has less substrate available to maintain muscle.
Weight loss is not the same as fat loss
Scale weight can drop while lean tissue drops alongside it. Because muscle loss is not something you feel in the first month, the useful signals are strength, endurance, and what you can physically do rather than the number itself.
This is not unique to GLP-1 medications
Lean mass loss is a recognized feature of weight loss generally, including caloric restriction without medication. What is different with GLP-1 therapy is the pace, and pace is what compresses the window in which nutrition and training have to catch up.
What the 2026 evidence actually shows
The meta-analysis figures, in context
The 2026 review in the International Journal of Obesity pooled seven randomized controlled trials covering 821 patients receiving obesity-dose GLP-1 receptor agonists. It reported an increase of 1.81% in lean mass as a proportion of total body weight, alongside a decrease of 1.74 kg in absolute lean mass and a 3.06% decrease in lean mass percentage.
Read together, those results say that the composition of what remains can improve while the absolute quantity of muscle still falls. Neither figure makes GLP-1 therapy a bad choice. Both make the case for planning around it.
What is being studied next
Research is now testing whether the loss can be blunted directly. A phase 2 randomized, double-blind, placebo-controlled trial of apitegromab, an agent targeting myostatin signaling, was published in Nature Medicine in 2026 and examined lean mass preservation during tirzepatide-induced weight loss in adults. Separately, the LEAN-PREP trial registered on ClinicalTrials.gov is testing whether adding protein and resistance exercise preserves lean mass in adults with obesity on semaglutide or tirzepatide. Neither is a treatment you can act on today, and neither changes the fundamentals.
The plan that has support behind it
Protein, distributed across the day
A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society treats protein as a core priority during GLP-1 therapy for obesity. Meeting a target once a day is not the same as distributing it, and nausea or early fullness can make either version harder. The practical work is making protein easier to consume without dropping its quality.
Resistance training as the loading signal
Protein without mechanical loading is only half the input. Structured resistance exercise is what signals that the tissue is still needed, and it is why the advisory pairs the two rather than ranking them. Cleveland Clinic’s patient education on exercising while taking GLP-1 medications suggests starting with 10 to 15 minutes a day of light activity such as walking or stationary cycling if you are not already training, then building as the dose increases.
Monitoring function, not just weight
We track what you can do: stair tolerance, recovery time between sessions, the ability to rise from a chair without using your arms. Those are the measures that catch a problem while it is still reversible, and they are more informative week to week than body weight. Reviews of lean mass preservation in GLP-1-based obesity treatment consistently place monitoring alongside nutrition and exercise rather than after them.
When joint pain is the thing blocking your training
The loop that forms
If a painful knee or hip keeps resistance training inconsistent, muscle loss accelerates, and weaker muscle loads the joint worse. That loop is common in people starting GLP-1 therapy, because the same population often carries degenerative joint disease.
Where orthobiologics honestly fit
The role of an orthobiologic here is to remove a barrier to training, not to substitute for it. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement; no orthobiologic has been shown to regrow or regenerate cartilage, and we do not describe any of them that way. What each option involves is set out in our approach to conservative-first care.
Conservative measures first
We work through conservative care before anything else, and surgery is considered only after conservative measures have been exhausted. Our office is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; details are on our St. Louis location page.
Peptide and longevity medicine in this conversation
Discussed, not sold
Patients often ask whether a peptide could help with appetite, body composition, or recovery while on a GLP-1. At Regen.MD peptides are discussed as clinical and educational subjects. They are not sold, and they are not positioned as a shortcut around protein and training.
Where the metabolic picture matters
Inflammatory load, recovery capacity, and baseline muscle reserve all shape how well you hold lean mass during rapid weight loss. Those are worth evaluating, and they belong alongside the medication decision rather than in place of it.
Build the muscle-preservation plan before you need it
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Frequently asked questions
How do GLP-1 medications and muscle loss end up connected?
Appetite reduction lowers total intake, and if protein and resistance training do not keep pace, lean mass is lost alongside fat. The speed of GLP-1-driven weight loss is what raises the stakes, because the nutrition and training plan has to be in place from the start rather than added later. Our peptide and metabolic medicine education covers the wider physiology.
Will more protein alone protect my muscle?
Probably not on its own. The joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society pairs protein intake with structured resistance exercise, because loading is the signal that tells the body to keep the tissue. We work through both in the context of the conditions we evaluate.
What should I watch for if I feel weaker after starting a GLP-1?
Stairs feeling harder, slower recovery from activity, difficulty rising from a chair, or a training plateau at a weight you used to handle. Treat those as information rather than as normal adjustment, and take them back to your prescribing clinician before changing anything. If joint pain is part of what is limiting you, see our orthobiologics service page.
Can an injection fix the problem if joint pain is stopping me from training?
It can sometimes remove a barrier, but it does not replace the nutrition and strength plan. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement, and no orthobiologic has been shown to regrow cartilage. Our patient education library sets out how we frame those limits.
Who reviews my regimen?
The Clinical Evaluation is physician-led and looks at your GLP-1 regimen alongside your day-to-day function, not just your weight trend. You can read the background of Dr. Gurpreet Singh Padda, MD, MBA, MHP before requesting one.
Sources
- Gallup. In U.S., GLP-1 Usage Reaches New High. July 7, 2026. https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx — referenced for the finding that 11% of U.S. adults currently take GLP-1 medications for weight loss purposes.
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). International Journal of Obesity, 2026. https://www.nature.com/articles/s41366-026-02118-y — referenced for the seven included studies and 821 patients, the 1.81% increase in lean mass as a proportion of total weight, the 1.74 kg decrease in absolute lean mass, and the 3.06% decrease in lean mass percentage.
- Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/ — referenced for the emphasis on protein intake and structured resistance exercise during GLP-1-mediated weight loss.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13303403/ — referenced for the placement of monitoring alongside nutrition and exercise in lean mass preservation strategies.
- Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obesity Reviews, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11611443/ — referenced for skeletal muscle loss as a recognized feature of weight loss generally, including caloric restriction without medication.
- Cleveland Clinic. Taking GLP-1s? Make Sure You Exercise. Patient education article, May 5, 2026. https://health.clevelandclinic.org/exercise-for-glp-1-use — referenced for the suggestion to start with 10 to 15 minutes a day of light activity such as walking or stationary cycling.
- ClinicalTrials.gov. LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy (LEAN-PREP Study). NCT06885736, Dasman Diabetes Institute, recruiting. https://clinicaltrials.gov/study/NCT06885736 — referenced for the trial testing protein plus resistance exercise for lean mass preservation in adults with obesity.
- Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, July 2026. https://pubmed.ncbi.nlm.nih.gov/42260100/ — referenced for the phase 2 investigation of myostatin-pathway inhibition during tirzepatide-induced weight loss.